Original ArticleNo Access

The Effect of Ex-Vivo Hyaluronic Acid on Myofibroblast and Collagen in Dupuytren Disease

Payaslı Clinic, Plastic Reconstructive and Aesthetic Surgery, Private Practice, Istanbul, Turkey

Department of Plastic Reconstructive and Aesthetic Surgery, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey

E-mail Address: caglamutkan2002@yahoo.com

Correspondence to: Çağla Çiçek, Cevizli Mh Şemsi Denizer Cad. E-5 Karayolu Cevizli Mevkii, Kartal, İstanbul 34890, Turkey. Tel: +90-536-933-3874.

Search for more papers by this author

Gaye FİLİNTE

Department of Plastic Reconstructive and Aesthetic Surgery, University of Health Science, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey

Search for more papers by this author

, and

Ülkügül GÜVEN

Department of Biochemistry, Genetic and Metabolic Diseases Research and Investigation Center, Marmara University School of Medicine, Istanbul, Turkey

Search for more papers by this author

https://doi.org/10.1142/S2424835522500916Cited by:0 (Source: Crossref)

Abstract

Background: Dupuytren disease (DD) is characterised by increased myofibroblast/fibroblast activity and type3/type1 collagen ratios. Hyaluronic acid (HA) is major component of the extracellular matrix and some studies have showed that HA limits myofibroblast activity and decreases type3/type1 collagen ratio. The aim of this study is to determine the effect of the ex-vivo application of HA on cultured fibroblasts obtained from normal and diseased tissue from patients with DD. This is the initial step towards defining the use of HA as a new approach for medical treatment of DD.

Methods: Tissue samples were obtained from both healthy forearm (C) and unhealthy palmar (D) fascia of patients undergoing surgery for DD. Tissue samples were cultured and divided into four groups depending on the addition of HA [C(HA−), C(HA+), D(HA−) and D(HA+)]. The tissues were evaluated using Western blot to detect effect of HA on myofibroblast (by measuring alpha smooth muscle actin [α-SMA) and on the ratio of type3/type1 collagen by measuring collagen type1 alpha 1 Chain (COL1A1) and collagen type3 alpha 1 Chain (COL3A1).

Results: The rate of the average α-SMA value in the D(HA+) group was significantly lower compared to that of the D(HA−) group. The average ratio of type3/type1 collagen in the D(HA+) group was significantly lower compared to the D(HA−) group.

Conclusions: The ex-vivo application of HA on cultured fibroblasts obtained from patients with DD resulted in a decrease in myofibroblast/fibroblast activity and type3/type1 collagen ratios. This may pave the way for clinical application of HA in the treatment of DD.

Keywords:

REFERENCES

1. Grazina R, Teixeira S, Ramos R, Sousa H, Ferreira A, Lemos R. Dupuytren disease: Where do we stand? EFORT Open Rev. 2019;4(2):63–69. https://doi.org/10.1302/2058-5241.4.18002. Crossref, Medline, Google Scholar
2. Rodrigues JN, Becker GW, Ball C, et al.. Surgery for Dupuytren’s contracture of the fingers. Cochrane Database Syst Rev. 2015;2015(12):CD010143. https://doi.org/10.1002/14651858.CD010143.pub2. Crossref, Medline, Google Scholar
3. Walthall J, Anand P, Rehman UH. Dupuytren contracture. In: StatPearls. StatPearls Publishing; November 9, 2021. Google Scholar
4. Bogdanov I, Rowland Payne C. Dupuytren contracture as a sign of systemic disease. Clin Dermatol. 2019;37(6):675–678. https://doi.org/10.1016/j.clindermatol.2019.07.027. Crossref, Medline, Google Scholar
5. Chung KW, Song SH, Kim MS. Synergistic effect of copper and amino acid mixtures on the production of extracellular matrix proteins in skin fibroblasts. Mol Biol Rep. 2021;48(4):3277–3284. https://doi.org/10.1007/s11033-021-06403-z. Crossref, Medline, Google Scholar
6. Shendi D, Marzi J, Linthicum W, et al.. Hyaluronic acid as a macromolecular crowding agent for production of cell-derived matrices. Acta Biomater. 2019;100:292–305. https://doi.org/10.1016/j.actbio.2019.09.042. Crossref, Medline, Google Scholar
7. Jannuzzi AT, Arslan S, Yilmaz AM, et al.. Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib. Redox Biol. 2020;32:101502. https://doi.org/10.1016/j.redox.2020.101502. Crossref, Medline, Google Scholar
8. Soreide E, Murad MH, Denbeigh JM, et al.. Treatment of Dupuytren’s contracture: A systematic review. Bone Joint J. 2018;100-B(9):1138–1145. https://doi.org/10.1302/0301-620X.100B9.BJJ-2017-1194.R2. Crossref, Medline, Google Scholar
9. Smeraglia F, Del Buono A, Maffulli N. Collagenase Clostridium histolyticum in Dupuytren contracture: A systematic review. Br Med Bull. 2016;118(1):149–158. https://doi.org/10.1093/bmb/ldw020. Crossref, Medline, Google Scholar
10. Meek RM, McLellan S, Reilly J, Crossan JF. The effect of steroids on Dupuytren disease: Role of programmed cell death. J Hand Surg Br. 2002;27(3):270–273. https://doi.org/10.1054/jhsb.2001.0742. Crossref, Medline, Google Scholar
11. McMillan C, Binhammer P. Steroid injection and needle aponeurotomy for Dupuytren disease: Long-term follow-up of a randomized controlled trial. J Hand Surg Am. 2014;39(10):1942–1947. https://doi.org/10.1016/j.jhsa.2014.07.018. Crossref, Medline, Google Scholar
12. Hurst LC, Badalamente MA. Nonoperative treatment of Dupuytren disease. Hand Clin. 1999;15(1):97–107, vii. Crossref, Medline, Google Scholar
13. Kırk JE, Chıeffı M. Tocopherol administration to patients with Dupuytren’s contracture; effect on plasma tocopherol levels and degree of contracture. Proc Soc Exp Biol Med. 1952;80(4):565–568. https://doi.org/10.3181/00379727-80-19692. Crossref, Medline, Google Scholar
14. Kadhum M, Smock E, Khan A, Fleming A. Radiotherapy in Dupuytren disease: A systematic review of the evidence. J Hand Surg Eur Vol. 2017;42(7):689–692. https://doi.org/10.1177/1753193417695996. Crossref, Medline, Google Scholar
15. Ball C, Izadi D, Verjee LS, Chan J, Nanchahal J. Systematic review of non-surgical treatments for early Dupuytren disease. BMC Musculoskelet Disord. 2016;17(1):345. https://doi.org/10.1186/s12891-016-1200-y. Crossref, Medline, Google Scholar
16. Neuman MG, Nanau RM, Oruña-Sanchez L, Coto G. Hyaluronic acid and wound healing. J Pharm Pharm Sci. 2015;18(1):53–60. https://doi.org/10.18433/j3k89d. Crossref, Medline, Google Scholar
17. Croce MA, Dyne K, Boraldi F, et al.. Hyaluronan affects protein and collagen synthesis by in vitro human skin fibroblasts. Tissue Cell. 2001;33(4):326–331. https://doi.org/10.1054/tice.2001.0180. Crossref, Medline, Google Scholar
18. Mast BA, Diegelmann RF, Krummel TM, Cohen IK. Hyaluronic acid modulates proliferation, collagen and protein synthesis of cultured fetal fibroblasts. Matrix. 1993;13(6):441–446. https://doi.org/10.1016/s0934-8832(11)80110-1. Crossref, Medline, Google Scholar
19. Osti L, Berardocco M, di Giacomo V, Di Bernardo G, Oliva F, Berardi AC. Hyaluronic acid increases tendon derived cell viability and collagen type I expression in vitro: Comparative study of four different hyaluronic acid preparations by molecular weight [published correction appears in BMC Musculoskelet Disord. 2015;16:334]. BMC Musculoskelet Disord. 2015;16:284. https://doi.org/10.1186/s12891-015-0735-7. Crossref, Medline, Google Scholar
20. Evanko SP, Potter-Perigo S, Petty LJ, Workman GA, Wight TN. Hyaluronan controls the deposition of fibronectin and collagen and modulates TGF-β1 induction of lung myofibroblasts. Matrix Biol. 2015;42:74–92. https://doi.org/10.1016/j.matbio.2014.12.001. Crossref, Medline, Google Scholar
21. Nugteren HM, Nijman JM, de Jong IJ, van Driel MF. The association between Peyronie’s and Dupuytren disease. Int J Impot Res. 2011;23(4):142–145. https://doi.org/10.1038/ijir.2011.18. Crossref, Medline, Google Scholar
22. Mohede DCJ, Riesmeijer SA, de Jong IJ, Werker PMN, van Driel MF. Prevalence of Peyronie and Ledderhose diseases in a series of 730 patients with Dupuytren disease. Plast Reconstr Surg. 2020;145(4):978–984. https://doi.org/10.1097/PRS.0000000000006642. Crossref, Medline, Google Scholar